VALIDATED EXECUTIVE ENGAGEMENTS
POOL + OUTREACH
2678
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
482
Interactions with Platform & by Email
PARTICIPANTS
82
Unique # Participated
VALIDATIONS
37
Responses Validated*
* Login to view program details and full enterprise executive list.
DATE
JULY 2020
TABLES
108
PAGES
180
EDITION
7
PRICE
USD $4950
It Pays to Understand the Dynamics of Competition in Your Business Ecosystem.
Who Are Your Competitors in the Scleroderma Diagnostics and Therapeutics Market?
Amid the COVID-19 crisis, the global market for Scleroderma Diagnostics and Therapeutics estimated at US$2 Billion in the year 2020, is projected to reach a revised size of US$4 Billion by 2027, growing at a CAGR of 10.3% over the period 2020-2027.Localized, one of the segments analyzed in the report, is projected to grow at a 9.5% CAGR to reach US$1.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Systemic segment is readjusted to a revised 11% CAGR for the next 7-year period. This segment currently accounts for a 49.9% share of the global Scleroderma Diagnostics and Therapeutics market.
The Scleroderma Diagnostics and Therapeutics market in the U.S. is estimated at US$598.9 Million in the year 2020. The country currently accounts for a 29.66% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$692.8 Million in the year 2027 trailing a CAGR of 9.6% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.4% and 8.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR while Rest of European market (as defined in the study) will reach US$692.8 Million by the year 2027.We bring years of research experience to this 7th edition of our report. The 180-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Actelion Pharmaceuticals Ltd.; Bayer AG; Boehringer Ingelheim International GmbH; Corbus Pharmaceuticals Holdings, Inc.; Cumberland Pharmaceuticals, Inc.; Cytori Therapeutics, Inc.; Gilead Sciences, Inc.; Pfizer, Inc.; Sanofi SA
» Drug Class (Corticosteroids, Immunosuppressive Agents, Endothelin receptor antagonists, Calcium Channel Blockers, Other Drug Classes) » Indication (Localized, Systemic)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
INSIDER ACCESS PRIVILEGES
Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.
KEY DIFFERENTIATORS
We are firmly committed to build upon perspectives from global executive insights. These engagements enrich our projects. Our primary research programs are fully validated and accessible by clients. (Its a common industry-wide* practice that no validated primary research is done! For the most part, remote resident analysts curate and write reports drawing on search engine research and data modeling.
* A review of 262 off-the-shelf market report publishers worldwide.
WHAT SETS US APART
Client companies can access multiple features on our MarketGlass™ platform.
Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.
Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)
A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.
Where relevent and possible we present competitive brands.
Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.
Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.
Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.
We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.
05
| I. INTRODUCTION, METHODOLOGY & REPORT SCOPE |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Global Competitor Market Shares |
| Scleroderma Diagnostics and Therapeutics Competitor Market Share Scenario Worldwide (in %): 2019 & 2025 |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| Scleroderma Diagnostics and Therapeutics Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 |
| Scleroderma Diagnostics and Therapeutics Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2009-2017 |
| Scleroderma Diagnostics and Therapeutics Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 |
| Corticosteroids (Drug Class) Geographic Market Spread Worldwide in US$ Thousand: 2018 to 2025 |
| Corticosteroids (Drug Class) Region Wise Breakdown of Global Historic Demand in US$ Thousand: 2009 to 2017 |
| Corticosteroids (Drug Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 |
| Immunosuppressive Agents (Drug Class) World Market Estimates and Forecasts by Region/Country in US$ Thousand: 2018 to 2025 |
| Immunosuppressive Agents (Drug Class) Market Historic Review by Region/Country in US$ Thousand: 2009 to 2017 |
| Immunosuppressive Agents (Drug Class) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 |
| Endothelin receptor antagonists (Drug Class) World Market by Region/Country in US$ Thousand: 2018 to 2025 |
| Endothelin receptor antagonists (Drug Class) Historic Market Analysis by Region/Country in US$ Thousand: 2009 to 2017 |
| Endothelin receptor antagonists (Drug Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 |
| Calcium Channel Blockers (Drug Class) World Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018 to 2025 |
| Calcium Channel Blockers (Drug Class) Market Worldwide Historic Review by Region/Country in US$ Thousand: 2009 to 2017 |
| Calcium Channel Blockers (Drug Class) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025 |
| Other Drug Classes (Drug Class) Market Opportunity Analysis Worldwide in US$ Thousand by Region/Country: 2018 to 2025 |
| Other Drug Classes (Drug Class) Global Historic Demand in US$ Thousand by Region/Country: 2009 to 2017 |
| Other Drug Classes (Drug Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 |
| Localized (Indication) World Market by Region/Country in US$ Thousand: 2018 to 2025 |
| Localized (Indication) Historic Market Analysis by Region/Country in US$ Thousand: 2009 to 2017 |
| Localized (Indication) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 |
| Systemic (Indication) Potential Growth Markets Worldwide in US$ Thousand: 2018 to 2025 |
| Systemic (Indication) Historic Market Perspective by Region/Country in US$ Thousand: 2009 to 2017 |
| Systemic (Indication) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 |
| III. MARKET ANALYSIS |
| GEOGRAPHIC MARKET ANALYSIS |
| UNITED STATES |
| Market Facts & Figures |
| US Scleroderma Diagnostics and Therapeutics Market Share (in %) by Company: 2019 & 2025 |
| United States Scleroderma Diagnostics and Therapeutics Market Estimates and Projections in US$ Thousand by Drug Class: 2018 to 2025 |
| Scleroderma Diagnostics and Therapeutics Market in the United States by Drug Class: A Historic Review in US$ Thousand for 2009-2017 |
| United States Scleroderma Diagnostics and Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| United States Scleroderma Diagnostics and Therapeutics Market Estimates and Projections in US$ Thousand by Indication: 2018 to 2025 |
| Scleroderma Diagnostics and Therapeutics Market in the United States by Indication: A Historic Review in US$ Thousand for 2009-2017 |
| United States Scleroderma Diagnostics and Therapeutics Market Share Breakdown by Indication: 2009 VS 2019 VS 2025 |
| CANADA |
| Canadian Scleroderma Diagnostics and Therapeutics Market Estimates and Forecasts in US$ Thousand by Drug Class: 2018 to 2025 |
| Canadian Scleroderma Diagnostics and Therapeutics Historic Market Review by Drug Class in US$ Thousand: 2009-2017 |
| Scleroderma Diagnostics and Therapeutics Market in Canada: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025 |
| Canadian Scleroderma Diagnostics and Therapeutics Market Estimates and Forecasts in US$ Thousand by Indication: 2018 to 2025 |
| Canadian Scleroderma Diagnostics and Therapeutics Historic Market Review by Indication in US$ Thousand: 2009-2017 |
| Scleroderma Diagnostics and Therapeutics Market in Canada: Percentage Share Breakdown of Sales by Indication for 2009, 2019, and 2025 |
| JAPAN |
| Japanese Market for Scleroderma Diagnostics and Therapeutics: Annual Sales Estimates and Projections in US$ Thousand by Drug Class for the Period 2018-2025 |
| Scleroderma Diagnostics and Therapeutics Market in Japan: Historic Sales Analysis in US$ Thousand by Drug Class for the Period 2009-2017 |
| Japanese Scleroderma Diagnostics and Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| Japanese Market for Scleroderma Diagnostics and Therapeutics: Annual Sales Estimates and Projections in US$ Thousand by Indication for the Period 2018-2025 |
| Scleroderma Diagnostics and Therapeutics Market in Japan: Historic Sales Analysis in US$ Thousand by Indication for the Period 2009-2017 |
| Japanese Scleroderma Diagnostics and Therapeutics Market Share Analysis by Indication: 2009 VS 2019 VS 2025 |
| CHINA |
| Chinese Scleroderma Diagnostics and Therapeutics Market Growth Prospects in US$ Thousand by Drug Class for the Period 2018-2025 |
| Scleroderma Diagnostics and Therapeutics Historic Market Analysis in China in US$ Thousand by Drug Class: 2009-2017 |
| Chinese Scleroderma Diagnostics and Therapeutics Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Chinese Scleroderma Diagnostics and Therapeutics Market Growth Prospects in US$ Thousand by Indication for the Period 2018-2025 |
| Scleroderma Diagnostics and Therapeutics Historic Market Analysis in China in US$ Thousand by Indication: 2009-2017 |
| Chinese Scleroderma Diagnostics and Therapeutics Market by Indication: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| EUROPE |
| Market Facts & Figures |
| European Scleroderma Diagnostics and Therapeutics Market: Competitor Market Share Scenario (in %) for 2019 & 2025 |
| European Scleroderma Diagnostics and Therapeutics Market Demand Scenario in US$ Thousand by Region/Country: 2018-2025 |
| Scleroderma Diagnostics and Therapeutics Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2009-2017 |
| European Scleroderma Diagnostics and Therapeutics Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 |
| European Scleroderma Diagnostics and Therapeutics Market Estimates and Forecasts in US$ Thousand by Drug Class: 2018-2025 |
| Scleroderma Diagnostics and Therapeutics Market in Europe in US$ Thousand by Drug Class: A Historic Review for the Period 2009-2017 |
| European Scleroderma Diagnostics and Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| European Scleroderma Diagnostics and Therapeutics Market Estimates and Forecasts in US$ Thousand by Indication: 2018-2025 |
| Scleroderma Diagnostics and Therapeutics Market in Europe in US$ Thousand by Indication: A Historic Review for the Period 2009-2017 |
| European Scleroderma Diagnostics and Therapeutics Market Share Breakdown by Indication: 2009 VS 2019 VS 2025 |
| FRANCE |
| Scleroderma Diagnostics and Therapeutics Market in France by Drug Class: Estimates and Projections in US$ Thousand for the Period 2018-2025 |
| French Scleroderma Diagnostics and Therapeutics Historic Market Scenario in US$ Thousand by Drug Class: 2009-2017 |
| French Scleroderma Diagnostics and Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| Scleroderma Diagnostics and Therapeutics Market in France by Indication: Estimates and Projections in US$ Thousand for the Period 2018-2025 |
| French Scleroderma Diagnostics and Therapeutics Historic Market Scenario in US$ Thousand by Indication: 2009-2017 |
| French Scleroderma Diagnostics and Therapeutics Market Share Analysis by Indication: 2009 VS 2019 VS 2025 |
| GERMANY |
| Scleroderma Diagnostics and Therapeutics Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Drug Class for the Period 2018-2025 |
| German Scleroderma Diagnostics and Therapeutics Historic Market Analysis in US$ Thousand by Drug Class: 2009-2017 |
| German Scleroderma Diagnostics and Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Scleroderma Diagnostics and Therapeutics Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Indication for the Period 2018-2025 |
| German Scleroderma Diagnostics and Therapeutics Historic Market Analysis in US$ Thousand by Indication: 2009-2017 |
| German Scleroderma Diagnostics and Therapeutics Market Share Breakdown by Indication: 2009 VS 2019 VS 2025 |
| ITALY |
| Italian Scleroderma Diagnostics and Therapeutics Market Growth Prospects in US$ Thousand by Drug Class for the Period 2018-2025 |
| Scleroderma Diagnostics and Therapeutics Historic Market Analysis in Italy in US$ Thousand by Drug Class: 2009-2017 |
| Italian Scleroderma Diagnostics and Therapeutics Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Italian Scleroderma Diagnostics and Therapeutics Market Growth Prospects in US$ Thousand by Indication for the Period 2018-2025 |
| Scleroderma Diagnostics and Therapeutics Historic Market Analysis in Italy in US$ Thousand by Indication: 2009-2017 |
| Italian Scleroderma Diagnostics and Therapeutics Market by Indication: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| UNITED KINGDOM |
| United Kingdom Market for Scleroderma Diagnostics and Therapeutics: Annual Sales Estimates and Projections in US$ Thousand by Drug Class for the Period 2018-2025 |
| Scleroderma Diagnostics and Therapeutics Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Drug Class for the Period 2009-2017 |
| United Kingdom Scleroderma Diagnostics and Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| United Kingdom Market for Scleroderma Diagnostics and Therapeutics: Annual Sales Estimates and Projections in US$ Thousand by Indication for the Period 2018-2025 |
| Scleroderma Diagnostics and Therapeutics Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Indication for the Period 2009-2017 |
| United Kingdom Scleroderma Diagnostics and Therapeutics Market Share Analysis by Indication: 2009 VS 2019 VS 2025 |
| REST OF EUROPE |
| Rest of Europe Scleroderma Diagnostics and Therapeutics Market Estimates and Forecasts in US$ Thousand by Drug Class: 2018-2025 |
| Scleroderma Diagnostics and Therapeutics Market in Rest of Europe in US$ Thousand by Drug Class: A Historic Review for the Period 2009-2017 |
| Rest of Europe Scleroderma Diagnostics and Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Rest of Europe Scleroderma Diagnostics and Therapeutics Market Estimates and Forecasts in US$ Thousand by Indication: 2018-2025 |
| Scleroderma Diagnostics and Therapeutics Market in Rest of Europe in US$ Thousand by Indication: A Historic Review for the Period 2009-2017 |
| Rest of Europe Scleroderma Diagnostics and Therapeutics Market Share Breakdown by Indication: 2009 VS 2019 VS 2025 |
| ASIA-PACIFIC |
| Scleroderma Diagnostics and Therapeutics Market in Asia-Pacific by Drug Class: Estimates and Projections in US$ Thousand for the Period 2018-2025 |
| Asia-Pacific Scleroderma Diagnostics and Therapeutics Historic Market Scenario in US$ Thousand by Drug Class: 2009-2017 |
| Asia-Pacific Scleroderma Diagnostics and Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| Scleroderma Diagnostics and Therapeutics Market in Asia-Pacific by Indication: Estimates and Projections in US$ Thousand for the Period 2018-2025 |
| Asia-Pacific Scleroderma Diagnostics and Therapeutics Historic Market Scenario in US$ Thousand by Indication: 2009-2017 |
| Asia-Pacific Scleroderma Diagnostics and Therapeutics Market Share Analysis by Indication: 2009 VS 2019 VS 2025 |
| REST OF WORLD |
| Rest of World Scleroderma Diagnostics and Therapeutics Market Estimates and Forecasts in US$ Thousand by Drug Class: 2018 to 2025 |
| Rest of World Scleroderma Diagnostics and Therapeutics Historic Market Review by Drug Class in US$ Thousand: 2009-2017 |
| Scleroderma Diagnostics and Therapeutics Market in Rest of World: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025 |
| Rest of World Scleroderma Diagnostics and Therapeutics Market Estimates and Forecasts in US$ Thousand by Indication: 2018 to 2025 |
| Rest of World Scleroderma Diagnostics and Therapeutics Historic Market Review by Indication in US$ Thousand: 2009-2017 |
| Scleroderma Diagnostics and Therapeutics Market in Rest of World: Percentage Share Breakdown of Sales by Indication for 2009, 2019, and 2025 |
| IV. COMPETITION |
| Total Companies Profiled : 5 Click here to request a full table of contents and more details on this project. |
| V. CURATED RESEARCH |
INSIDER ACCESS TO
METHODOLOGY
QUESTIONNAIRE
INFLUENCER NETWORK
Registration is required to access our data stacks.
RESEARCH PANEL
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.
- Complimentary previews of full stack research data for participated
- Insider access to research programs including engagements and stats from other panelists
- Unlimited research credits of $1000 per participated project
- Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
- Interact with other panelists via our MarketGlassTM Data Exchange Platform*
- BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*
* Complete details will be shared with panelists upon formal acceptance.
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com